Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References EntrestoⓇ grew +44% in the quarter driven by expanded label in US, guideline 1,2 uptake and strong execution Sales evolution USD m, % cc YTD sales growth vs. PY US +30%, ex-US +53% US weekly NBRx3 New-to-brand prescriptions (000) Ex-US US +44% 924 +41% 2.6bn 5 632 1.8bn 1,407 519 + 318 866 405 314 Q3 2020 Q3 2021 9M 2020 9M 2021 See appendix for references 27 Investor Relations | Q3 2021 Results 3 1,192 915 2 7 01/19 04/19 - 07/19 - 10/19 - 01/20 04/20 - 07/20 - 10/20 - 01/21 - 04/21 - 07/21 - 10/21 - NOVARTIS | Reimagining Medicine

View entire presentation